Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced...

Company to showcase EsoGuard® and EsoCheck® at the conference's Innovation Pavilion NEW YORK, Oct. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a...

Initiative aims to increase awareness of the relationship between chronic heartburn and esophageal cancer, and role of EsoGuard esophageal precancer testing NEW YORK, Oct. 1, 2024 /PRNewswire/ --...

Follows the Society's strong endorsement of EsoGuard medical policy coverage by payors NEW YORK, Sept. 24, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a...

Leading experts to discuss advances in technologies to prevent esophageal cancer through esophageal precancer screening NEW YORK, Sept. 10, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq:...

Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters NEW YORK, Sept. 3, 2024 /PRNewswire/ -- Lucid...

Study demonstrates excellent analytical accuracy, repeatability, and reproducibility of the assay NEW YORK, Aug. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the...

Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal esophageal cancer NEW YORK, Aug. 13, 2024 /PRNewswire/ -- Lucid...

EsoGuard® test volume increased 31 percent quarterly; 44 percent annually Clinical data now well-positioned for final push towards broad coverage and reimbursement Over 50 high-volume...

Event held at Fort Worth Fire Department in partnership with Front Line Mobile Health NEW YORK, Aug. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a...